265 publications

Enter search criteria

Fill in keyword(s) to narrow your search.

Period from

Enter a start and/or end date here, using the following format: DD-MM-YYYY.

You can select a specific type of a publication you are looking for, such as press releases or speeches

Sort by: Date / Relevance

Apixaban (Eliquis) for the prevention of venous thromboembolic events

For the prevention of venous thromboembolic events in adults after a hip or knee replacement operation apixaban has an added ...

Report | 26-09-2011

Descriptions of pharmaceutical care provisions 2012 (BR/CU- 5056) – clarification within the framework of health insurance.

The Dutch Healthcare Authority (Nederlandse Zorgautoriteit, NZa) has approved a new ‘Descriptions of pharmaceutical care ...

Report | 29-08-2011

PCA3 medical test as diagnostic intervention for prostate cancer

CVZ has examined whether using the PCA3 gene expression test on patients with suspected prostate cancer and a negative initial ...

Report | 22-08-2011

Indications for proton therapy

Proton therapy is regarded as an insured provision for the indications head/neck tumours, breast cancer, lung cancer and prostate ...

Report | 22-08-2011

Ranibizumab (Lucentis) for the treatment of visual impairment due to diabetic macular oedema

Head-to-head trials have shown that, with respect to the intended and unintended effects, ranibizumab is superior to laser for ...

Report | 25-07-2011

Atomoxetine (Strattera) for the treatment of Attention Deficit Hyperactivity Disorder

The Medicinal Products Reimbursement Committee (CFH) has carried out a re-assessment of the medicine atomoxetine (Strattera). ...

Report | 27-06-2011

Lapatinib (Tyverb) in combination with an aromatase inhibitor for the indication metastatic HR+ HER2+ breast cancer

For postmenopausal patients with HR+ HER2+ metastatic breast cancer without rapid progression, without extensive visceral ...

Report | 27-06-2011

Amifampridine (Firdapse) for the symptomatic treatment of Lambert Eaton myasthenic syndrome (LEMS)

For the treatment of LEMS, amifampridine phosphate has an added therapeutic value in comparison with pyridostigmine. For the ...

Report | 27-06-2011

Prevention of panic disorders

Background reports show that for panic disorders sufficient scientific evidence exists for the efficacy of preventive ...

Report | 27-06-2011

Abarelix (Plenaxis) for the treatment of advanced hormone-dependent prostate cancer

Data from two head-to-head trials showed that abarelix was not inferior to the GnHR-agonist leuprolide. The unintended effects of ...

Report | 27-06-2011